167 related articles for article (PubMed ID: 11668417)
1. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
Sissi C; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
[TBL] [Abstract][Full Text] [Related]
2. Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns.
Sissi C; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2003 Dec; 29(6):661-70. PubMed ID: 14719183
[TBL] [Abstract][Full Text] [Related]
3. Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparins.
Sissi C; Lucatello L; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2002 Aug; 28(4):355-60. PubMed ID: 12244482
[TBL] [Abstract][Full Text] [Related]
4. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
5. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
Shimotori T; Sakuragawa N
Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
8. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
9. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin.
Mourier PA; Guichard OY; Herman F; Viskov C
Anal Biochem; 2014 May; 453():7-15. PubMed ID: 24561026
[TBL] [Abstract][Full Text] [Related]
11. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Ofosu FA; Smith LM; Anvari N; Blajchman MA
Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
Barrowcliffe TW; Thomas DP
Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
[TBL] [Abstract][Full Text] [Related]
13. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
Rosenberg RD
Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
[TBL] [Abstract][Full Text] [Related]
14. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
15. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
16. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
17. The role of Arg46 and Arg47 of antithrombin in heparin binding.
Arocas V; Bock SC; Olson ST; Björk I
Biochemistry; 1999 Aug; 38(31):10196-204. PubMed ID: 10433728
[TBL] [Abstract][Full Text] [Related]
18. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
19. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
[TBL] [Abstract][Full Text] [Related]
20. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Meddahi S; Samama MM
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
